Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis

JWL Brown; A Coles; D Horakova; E Havrdova; G Izquierdo; A Prat; M Girard; P Duquette; M Trojano; A Lugaresi; R Bergamaschi; P Grammond; R Alroughani; R Hupperts; P McCombe; V Van Pesch; P Sola; D Ferraro; F Grand'Maison; M Terzi; J Lechner-Scott; S Flechter; M Slee; V Shaygannejad; E Pucci; F Granella; V Jokubaitis; M Willis; C Rice; N Scolding; A Wilkins; OR Pearson; T Ziemssen; M Hutchinson; K Harding; J Jones; C McGuigan; H Butzkueven; T Kalincik; N Robertson

Journal article

Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis

JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, M Girard, P Duquette, M Trojano, A Lugaresi, R Bergamaschi, P Grammond, R Alroughani, R Hupperts, P McCombe, V Van Pesch, P Sola, D Ferraro, F Grand'Maison, M Terzi Show all

JAMA Journal of the American Medical Association | AMER MEDICAL ASSOC | Published : 2019

DOI: 10.1001/jama.2018.20588

Abstract

Importance: Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition. Objective: To determine the association between the use, the type of, and the timing of DMTs with the risk of conversion to secondary progressive MS diagnosed with a validated definition. Design, Setting, and Participants: Cohort study with prospective data from 68 neurology centers in 21 countries examining patients with relapsing-remitting MS commenc..

View full abstract

University of Melbourne Researchers

Tomas Kalincik Author

Richard MacDonell Author

Neil Shuey Author

Related Projects (3)

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Grants

Awarded by University of Melbourne

Funding Acknowledgements

This study was financially supported by National Health and Medical Research Council of Australia (fellowships 1140766 and 1080518, project grants 1129189 and 1083539), the University of Melbourne (Faculty of Medicine, Dentistry and Health Sciences research fellowship), a Next Generation Fellowship funded by the Grand Charity of the Freemason's (recipient JWLB), and the MSBase 2017 Fellowship (recipient JWLB). Alemtuzumab studies done in Cambridge were supported by the NIHR Cambridge Biomedical Research Centre and the MS Society UK. The MSBase Foundation is a not-for-profit organization that receives support from Roche, Merck, Biogen, Novartis, Bayer Schering, Sanofi Genzyme, and Teva.